Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.43 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | IDE | P14735 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901604 | 0.84 | CA2 (0.50) | LMNACA2SLC6A9ALDH1A1KDM4E | |
| SCHEMBL2825868 | 0.82 | LMNA (0.60) | LMNACA2AKR1C3AKR1C2G6PD | |
| SCHEMBL2825252 | 0.81 | LMNA (0.51) | LMNACA2AKR1C3AKR1C2G6PD | |
| SCHEMBL2823704 | 0.78 | LMNA (0.55) | LMNACA2AKR1C3AKR1C2G6PD | |
| SCHEMBL4448129 | 0.76 | LMNA (0.53) | LMNACA2AKR1C3AKR1C2KDM4E | |
| SCHEMBL8962352 | 0.76 | LMNA (0.70) | LMNAAKR1C3AKR1C2ALDH1A1KDM4E | |
| SCHEMBL17465966 | 0.76 | LMNA (0.60) | LMNAAKR1C3AKR1C2ALDH1A1KDM4E | |
| SCHEMBL4908760 | 0.75 | SLC6A9 (0.66) | SLC6A9AKR1C3 | |
| SCHEMBL3861678 | 0.74 | ALDH1A1 (0.62) | ALDH1A1KMT2A | |
| SCHEMBL2825373 | 0.74 | LMNA (0.50) | LMNACA2SLC6A9AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188139-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188139-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188139-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-7790763-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790763-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790763-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1838308-B1 | [4-(HETEROARYL)PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| EP-1848694-B1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | HOFFMANN LA ROCHE (CH) | 2009-11-25 | — | — | EP | disclosed |
| EP-1848694-B1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | HOFFMANN LA ROCHE (CH) | 2009-11-25 | — | — | EP | disclosed |
| EP-1844045-B1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-04 | — | — | EP | disclosed |
| WO-2006082001-A1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006082001-A1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006079467-A1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | F. HOFMANN-LA ROCHE AG (CH) | 2006-08-03 | — | — | WO | disclosed |
| US-20060167023-A1 | Substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-07-27 | — | — | US | disclosed |
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | US | disclosed |
| WO-2006077026-A1 | 2, 5-DISUBSTITUTED PHENYL METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-I) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRY DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160788-A1 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006072436-A1 | [4-(HETEROARYL) PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006072435-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| US-20060149062-A1 | Sulfanyl substituted phenyl methanones | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160788-A1 | Substituted phenyl methanone derivatives | SLC6A5, SLC6A1, SLC1A1 | LMNA 3619/4885CA2 3180/4885SLC6A9 18/4885 |
| US-20060167023-A1 | Substituted phenyl methanones | SLC6A7, SLC1A1, SLC26A3 | LMNA 2647/4885CA2 2621/4885SLC6A9 12/4885 |
| US-20060149062-A1 | Sulfanyl substituted phenyl methanones | SULT1A1, SULT2A1, SULT1E1 | LMNA 4147/4885CA2 2810/4885SLC6A9 19/4885 |
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | SLC1A2, SULT2A1, SLC6A5 | LMNA 3963/4885CA2 2023/4885SLC6A9 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.